Business Wire

CA-ENLIGHTED

23.5.2023 14:31:34 CEST | Business Wire | Press release

Share
Enlighted to Deliver Heavyweight Energy Savings, Productivity and Sustainability at New WWE HQ

Today Enlighted, a leading proptech company owned by Siemens, announced a new engagement with World Wrestling Entertainment (WWE) to support its vision of a smart, energy efficient headquarters. The leader in global entertainment that can be seen in more than 1 billion homes worldwide will use Enlighted’s intelligent lighting control, smart sensors, IoT data services and real time location services (RTLS) to achieve occupancy-based energy savings, optimal space management and provide the most productive environment for WWE employees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005437/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

WWE is headquartered in Stamford, Connecticut, with over 400,000 square feet of multi-purpose space including office space, studios, production and post-production facilities, conferencing, event, and outdoor terrace spaces. With the size and complexity of space types, it is essential for WWE to understand and optimize its real estate footprint using technology and software with the flexibility to address a range of uses. As part of a major renovation and digital transformation initiative, with almost 2,000 sensors over a wireless, fault-tolerant network at WWE will enable:

Enlighted Lighting Solution: Occupancy-based intelligent lighting control with flexible configurations for task tuning, daylight harvesting and efficient lighting of WWE spaces will result in bottom line energy savings and progression of WWE’s carbon neutrality.

Enlighted Data Services: Collecting data 65 times per second from sensors that measure movement, temperature and power, WWE will use specialized visualization dashboards to derive key insights for space design decisions.

Location Intelligence: WWE will use the same lighting sensing environment to reliably track assets, ranging from high value assets (memorabilia, collectibles) to operational assets (mail carts, merchandise samples, packages) in real-time for movement analysis and improved inventory management.

With Enlighted’s lighting controls as the foundation, WWE will be solving multiple IoT use cases and utilizing the open APIs, WWE will have central management, a ‘single pane of glass’ into operations.

“The new WWE headquarters is comprised of spaces intended for a variety of very different uses,” said Rajan Mehta, Chief Technology Officer, WWE. “The Enlighted IoT Smart Building technology will make it possible for us to realize enormous energy savings, increase our operating efficiencies and use data to capture building activity for intelligent data-driven space decisions. IoT-based asset tracking and process flow improvements will make our headquarters truly a smart building.”

“Space utilization isn’t just a matter of knowing how many people are in an office or production facility at a given moment—it’s about understanding how employees and guests are moving and interacting with spaces,” said Stefan Schwab, CEO of Enlighted. “The lighting-based sensors at WWE will capture vast amounts of data that WWE can use for a refined view of activity across all of their buildings. With the scalability of cloud storage, the company will be able to identify trends and preferences as they examine building usage data over time.”

About Enlighted

Enlighted is a leading proptech provider of IoT solutions at the intersection of people, space, and work. We offer a unique combination of cognitive environmental IoT sensors and lighting controls that connect to intelligent workplace experience apps, offering a singular, scalable, interoperable solution to address a spectrum of building, space, and productivity needs. Our customers leverage these solutions to enable occupant well-being, greater business efficiencies and momentum toward their sustainability goals. Enlighted is part of Building Robotics, Inc., a Siemens company. For more information, please visit us at enlightedinc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005437/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye